SAN DIEGO, Aug. 27, 2020 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical device technology company focused on
developing products to diagnose and treat life and organ
threatening diseases, today announced that CEO, Timothy C. Rodell, MD, is scheduled to present
to a live audience at the LD Micro 500 virtual investor conference
on Thursday, September 3, 2020 at
11:40 am Pacific Time (2:40 pm ET), and will be available for one-on-one
meetings with investors throughout the day on September 3, 2020.
The presentation will be aired live and available for replay at
the investor relations section of Aethlon Medical's website at
www.aethlonmedical.com.
The LD Micro 500 will take place September 1-4 and will feature some of the most
prominent companies in the micro-cap world, with 500 companies
expected to provide updates. Register here:
https://www.webcaster4.com/Webcast/Page/2019/36840. Those wishing
to listen to the presentation over the phone can dial into
877-407-6180 (domestic calls) or 201-689-8050 (international
calls).
Replays of the presentation will be available for three months.
The reply can be accessed through
https://www.webcaster4.com/Webcast/Page/2019/36840.
About Aethlon and the Hemopurifier®
Aethlon is focused
on addressing unmet needs in global health. The Aethlon
Hemopurifier is a clinical- stage immunotherapeutic device designed
to combat cancer and life-threatening viral infections. In cancer,
the Hemopurifier is designed to deplete the presence of circulating
tumor-derived exosomes that promote immune suppression.
These tumor derived exosomes also seed the spread of metastases
and inhibit the benefit of leading cancer therapies. The
Hemopurifier® is an FDA designated "Breakthrough Device" related to
the treatment of individuals with advanced or metastatic cancer who
are either unresponsive to or intolerant of standard of care
therapy, and with cancer types in which exosomes have been shown to
participate in the development or severity of the disease cancer.
The Hemopurifier also holds a Breakthrough Device designation
related to life-threatening viruses that are not addressed with
approved therapies.
Aethlon also owns 80% of Exosome Sciences, Inc., which is
focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com.
About LD Micro
LD Micro was founded in 2006 with the
sole purpose of being an independent resource in the microcap
space. What started out as a newsletter highlighting unique
companies has transformed into an event platform hosting several
influential conferences annually (Invitational, Summit, and Main
Event). In 2015, LDM launched the first pure microcap index (the
LDMi) to exclusively provide intraday information on the entire
sector. LD will continue to provide valuable tools for the benefit
of everyone in the small and microcap universe.
Company Contact:
Jim Frakes, CFO
jfrakes@aethlonmedical.com
858-459-7800 extension 3300
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-ld-micro-500-virtual-conference-301119380.html
SOURCE Aethlon Medical, Inc.